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Abstract 
Purpose: P38 mitogen-activated protein kinases (MAPK) level is an important prognostic factor in breast cancer. This 
study was performed to detect the expressions of P-p38 MAPK expression in breast cancer and explore their correla-
tions with clinicopathological factors.
Experimental design: Tumor samples from 355 Chinese patients diagnosed with invasive breast cancer and adja-
cent non-cancerous tissue were collected between 2003 and 2010. The expression of P-p38 MAPK was analyzed using 
immunohistochemical staining. The correlations between P-p38 MAPK expression and clinicopathological findings 
including age, AJCC Stage, Histologic characters, ER, PR, and HER2 were analyzed using the parametric correlation 
method. P-p38 MAPK was selected as dependent variable to perform multivariate analysis respectively at last.
Results: Overall, 161 (45 %) and 183 (52 %) of the 355 specimens showed positive P-p38 MAPK staining in the cyto-
plasm and nucleus respectively, which were significant higher than that in the adjacent non-cancerous tissues in both 
the cytoplasm and the nucleus. High P-p38 MAPK expression of cytoplasm and nucleus were both associated with 
positive PR status in luminal A/B type of breast cancer, and were both associated with positive HER2 status in HER2-
positive type of breast cancer. The result of multivariate analysis demonstrated that HER2 and PR were both signifi-
cantly association with P-p38 MAPK expression of cytoplasm and nucleus.
Conclusions: Our study suggests that P-p38 MAPK expression were significantly associated with clinicopathological 
factors and PR/HER2 might association with phosphorylation of p38 MAPK in different types of breast cancer.
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Background
According to the May Clinic, breast cancer is the second 
most common cancer after skin cancer in women in the 
United States and the most frequently diagnosed malig-
nancy among women worldwide (incidence, approxi-
mately 1.38 million per year) that results in 46 million 
deaths (Lee et  al. 2014; Jemal et  al. 2011). Activation of 
mitogen-activated protein kinases (MAPK) is one of 
the most important intracellular signal transduction 
pathways in breast carcinoma progression (Blenis 1993; 
Crews and Erikson 1993).
The MAPK family includes extracellular signal-regu-
lated kinase (ERK), c-Jun N-terminal kinase (JNK), and 
P38 MAPK (Lei et al. 2014). As a member of the MAPK 
family, P38 MAPK has been identified as the critical 
point for a normal immune and inflammatory response 
as the point of convergence of intracellular downstream 
growth factor receptor signaling (Cuenda and Rousseau 
2007) and the level of them is reportedly associated with 
advanced stage and short survival in cancers of the breast 
(Esteva et al. 2004), prostate (Park et al. 2003; Khandrika 
et al. 2009), bladder (Kumar et al. 2010), liver (Iyoda et al. 
2003), and lung (Greenberg et al. 2002; Koul et al. 2013). 
Activation of P38 MAPK could result in induction of 
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gene expression, leading to increased proliferation, inva-
sion, and metastasis in solid cancer (Koul et  al. 2013; 
Mo et al. 2012) and endogenous p38 MAPK activity also 
reportedly correlates well with breast carcinoma cell 
invasiveness (Huang et al. 2000; Tang and Han 2013).
The activated form of p38 MAPK, phosphoryla-
tion of p38 MAPK (P-p38 MAPK) has been reported in 
response to ultraviolet irradiation, biologic inducers (e.g., 
growth factors and cytokines), and chemicals (Dérijard 
et  al. 1994). Levels of P-p38 MAPK have been reported 
to elevate in breast cancer cells and may be associated 
with poor overall survival (OS) in patients with lymph 
node–positive breast carcinoma with adjuvant chemo-
therapy while location of P-p38 MAPK was not men-
tioned (Esteva et al. 2001, 2004). Davidsone et al. (2006) 
also showed that a higher p38 activation ratio correlated 
with shorter OS in a total of 19 cases. Even so, the expres-
sion of P-p38 MAPK in breast cancer and the associated 
with clinical factors were still not well studied due to a 
lack of sufficient data.
Based on a total of 355 patients with primary invasive 
breast carcinoma, the primary goal of the current study 
was to explore the prevalence of P-p38 MAPK expression 
and their possible roles in breast cancer. Our observa-
tion might direct further investigation on the functions 
of P-p38 MAPK and influence factor of its expression so 




All of the specimens used in this study were used after 
each patient provided written informed consent. The 
Ethics Committee of Changhai Hospital granted study 
approval. The authors confirm that necessary consent 
was obtained from every patient involved in this study for 
both participation and publication.
Study population
Specimens of patients who were diagnosed with pri-
mary invasive breast cancer and underwent a surgical 
procedure between January 2003 and December 2010 at 
the First Affiliated Hospital of Second Military Medical 
University (Changhai Hospital, Shanghai, China) were 
evaluated. Each tumor was classified according to the 
tumor-node-metastasis (TNM) classification [American 
Joint Committee on Cancer (AJCC) stage]. Patient age 
at diagnosis, menopausal status, largest tumor diameter, 
number of lymph node metastases, TNM stage (AJCC), 
histological type, and histology grade (Elston-Ellis grade) 
were recorded with ER, PR, and HER2 expressions. All of 
the included patients were treated according to National 
Comprehensive Cancer Network guidelines, which 
recommend the use of anthracycline-based regimens 
or anthracycline +  taxane-based regimens according to 
lymph node metastasis status. Anti-hormone and anti-
HER2 therapy for patients was used according to ER and 
HER2 expression status.
Among those cases, patients with stage IV disease, a 
non-curative resection, or another primary tumor site 
and those who received preoperative radiotherapy or 
chemotherapy were excluded. Patients who were not 
treated according to these guidelines were also excluded. 
We ultimately included a total of 300 patients with inva-
sive breast cancer in this study. The median patient age 
was 53 (range 31–84) years, while the median OS was 56 
(range 3–115) months.
Tissue microarray and immunohistochemistry
Paraffin-embedded pathological specimens were 
obtained from the surgically resected tissues. All of these 
resection samples were treated with a standard fixation, 
dissection, and processing protocol. In addition, 300 
pericarcinoma tissue samples were collected as a control 
group.
To examine the typical pathological changes, a large 
tissue microarray (TMA) was used. TMA blocks were 
constructed using a tissue arraying instrument (Beecher 
Instruments, Sun Prairie, WI, USA). Cylinders (1.5  mm 
in diameter) of representative areas of a tissue block 
were punched from the center of the tumor away from 
the areas of ulceration and necrosis and re-embedded in 
a defined position within a recipient paraffin block. The 
TMA blocks were then cut into 4-mm sections and pro-
cessed for immunohistochemistry (IHC).
After being washed with phosphate-buffered saline, 
the specimens were incubated with the primary antibody 
using ER antibody (dilution 1:50), PR antibody (dilution 
1:50), HER2 antibody (dilution 1:50), and P-p38 MAPK 
antibody (dilution 1:40; Cell Signaling Technology Inc. 
Boston, USA). Immunostaining was conducted using the 
Envision System with diaminobenzidine (Dako, Glostrup, 
Denmark). A negative control was obtained by replac-
ing the primary antibody with normal murine or rabbit 
immunoglobulin G with the same dilution.
IHC evaluation
The P-p38 MAPK expressions in the TMA were inde-
pendently evaluated by three individuals (Bin Wang, 
Huayong Jiang, and Ning Ma) who were blinded to the 
patients’ clinicopathological data. Discrepancies were 
resolved by consensus among the three evaluators.
A positive HER2 result was determined by IHC stain-
ing of 3+ or of 2+ with a positive fluorescent in  situ 
hybridization result. P-p38 MAPK, ER, and PR receptors 
were all graded by the three independent observers using 
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a four-point scale on which 0 = no staining, 1+ =  light 
staining, 2+ = moderate staining, and 3+ = strong stain-
ing (Leake et  al. 2000; Mohammed et  al. 2012). Slices 
with a score of 1+ were classified as having “low expres-
sion,” those with 2+ as “high expression,” and those with 
3+ as “overexpression” (“positive”) in contrast to slices 
with a score of 0, which were classified as having “no 
expression” (“negative”).
Statistical analysis
The correlation analysis was used to find the possible 
association between P-p38 MAPK expression and the 
clinicopathological parameters. The Mann–Whitney U 
test was used to analyze the correlation between P-p38 
MAPK expression and patient age. Kaplan–Meier curves 
were plotted to assess the effect of P-p38 MAPK expres-
sion on OS. Different survival curves were compared 
using the log-rank test. Multivariate proportional Cox 
models were used to assess the prognostic significance of 
P-p38 MAPK expression, age, tumor stage, histological 
type, and HER2, ER, and PR expressions. P values ≤0.05 
were considered significant. The statistical analysis was 
performed using SPSS19.0 software (SPSS, Inc.).
Results
Staining of P‑p38 MAPK in breast cancers
P-p38 MAPK was expressed in the cytoplasm and 
nucleus but not in the membrane (Fig.  1). The expres-
sion level of P-p38 MAPK in the cytoplasm and nucleus 
were both calculated. Of all 355 cases, positive P-p38 
MAPK staining was seen in the cytoplasm of 161 (45 %) 
and in the nucleus of 183 (52  %) (P  =  0.421 between 
them). P-p38 MAPK expression levels in the cytoplasm 
and nucleus were both compared between in tumor tis-
sues and adjacent non-cancerous tissues. Positive P-p38 
MAPK staining was found in the cytoplasm in 115 (32 %) 
and in the nucleus in 133 (37  %) of all examined peri-
carcinoma tissue samples. P-p38 MAPK expression was 
higher in the tumor tissues than that in the adjacent non-
cancerous tissues in both the cytoplasm and the nucleus 
(P < 0.001 and <0.001, respectively; Table 1).
Association between P‑p38 MAPK expression 
and clinicopathological parameters
The correlation between P-p38 MAPK expression and 
clinicopathological parameters was also examined to 
further elucidate its prognostic value in invasive breast 
cancer. We found a significant correlation between P-p38 
MAPK expression and lymph node metastasis status and 
AJCC stage in the cytoplasm and nucleus (P = 0.012 and 
0.028 for lymph node metastasis status, and P  =  0.032 
and 0.047 for AJCC stage respectively) but not between 
P-p38 MAPK expression and age, menopause status, 
depth of invasion, histological classification and histolog-
ical type (P > 0.05; Table 2).
Association between P‑p38 MAPK expression and ER, PR, 
or HER2 expression
ER, PR and HER2 are the four well-known critical fac-
tors in breast cancer that guide its clinical treatment and 
prognosis. What is interesting that upon analyzing the 
association between P-p38 MAPK and ER, PR and HER2 
expression in overall breast cancer, we found the posi-
tive correlation between P-p38 MAPK in nucleus and PR 
(P = 0.000, R = 0.171), while did not found any positive 
correlation thing between P-p38 MAPK and ER, PR or 
HER2 in cytoplasm (Table 2).
These three parameters mentioned above are also most 
important in determining the four types of breast cancer 
types including ER-positive [luminal A subtype, luminal 
B subtype], HER2-positive subtype, and triple-negative 
subtype. Then the subtypes of breast cancer were studied 
one by one. We know that PRs are the products of the 
connection between estrogen and its receptor. As such, 
ER-positive breast cancer (luminal A and luminal B) 
was the focus of our observation. We then attempted to 
determine the correlation between P-p38 MAPK and PR 
expression in these two subtypes of breast cancer. Inter-
estingly, we found that this kind of positive correlation 
did exist both in cytoplasm and in the nucleus (P = 0.001, 
R = 0.220 in the cytoplasm and P = 0.000, R = 0.225 in 
the nucleus) while with ER (P = 0.025, R = 0.148) only in 
the cytoplasm.
What`s more, we also found a positive correlation 
between P-p38 MAPK expression and HER2 (P = 0.003, 
R  =  0.310 in the cytoplasm and P  =  0.013, R  =  0.257 
in the nucleus) in HER2-positive subtype. Nothing sig-
nificant correlation was found in triple-negative breast 
cancer.
ER+HER2+ luminal B breast cancer was then studied 
to clarify the correlation between P-p38 MAPK and PR 
or HER2 at last. As a result, we did find a positive correla-
tion between P-p38 MAPK expression and PR (P = 0.002, 
R = 0.294 in the cytoplasm and P = 0.001, R = 0.302 in 
the nucleus) while not HER2 (P = 0.062, R = 0.185 in the 
cytoplasm and P = 0.219, R = 0.121 in the nucleus).
Multivariate logistic regression analysis
Because TNM stage was dependent on tumor size and 
axillary lymph node metastasis, it was excluded in multi-
variate analysis. Variables that were selected for multivar-
iate analysis included P-p38 MAPK in cytoplasm, P-p38 
MAPK in nucleus, HER2, ER, PR, age at diagnosis, men-
opause, histology grade, histology type, depth of invasion 
(T), and regional lymph nodes (N). As Table  3 showed, 
Only PR was demonstrated a significant association with 
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P-p38 MAPK in cytoplasm and P-p38 MAPK in nucleus 
in overall breast cancer and PR was also demonstrated 
the only one which was a significant association in lumi-
nal A/B breast cancer. As a result, HER2 was also dem-
onstrated a significant correlated with P-p38 MAPK in 
HER2-Positive type breast cancer.
Discussion
In spit of the important role of p38 MAPK as an impor-
tant prognostic factor in breast cancer, the expression of 
P-p38 MAPK in breast cancer and the associated with 
clinical factors remains to be elucidated due to a lack of 
sufficient data up to now. In the present study, we found 
that P-p38 MAPK was expressed in both the cytoplasm 
and nucleus of breast cancer cells and positively corre-
lated with PR expression in those with the luminal A/B 
subtype while positively correlated with HER2 expression 
in those with the HER2-positive subtype only in both 
correlation analysis and multivariate logistic regression 
analysis.
We know that MKK3, MKK6 and SEK activate p38 
MAP kinase by phosphorylation at Thr180 and Tyr182 
together. The P-p38 MAPK mAb we chose has been made 
by Cell Signaling Technology America Inc. to specifically 
detect endogenous levels of p38 MAPK only when phos-
phorylated at Thr180 and Tyr182 (www.cellsignal.com). 
This antibody was used to detect p38 MAPK (including 
Fig. 1 Representative of breast cancer immunostaining for the P-p38 MAPK in the tumor tissues (a, b) and adjacent non-cancerous tissues (c, d). 
a Positive for breast cancer tissues. b Negative for breast cancer tissues. c Positive for adjacent non-cancerous tissues. d Negative for adjacent non-
cancerous tissues
Table 1 Diffrence of P-p38 MAPK expression between can-
cerous tissues and non-cancerous tissues
N Negative (%) Positive (%) P
P-p38 MAPK of cytoplasm
 Cancerous tissues 355 194 (55) 161 (45) <0.001
 Pericarcinoma tissues 355 240 (68) 115 (32)
P-p38 MAPK of nucleus
 Cancerous tissues 355 172 (48) 183 (52) <0.001
 Pericarcinoma tissues 355 222 (63) 133 (37)
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Table 2 Correlations between P-p38 MAPK expression and clinicopathologic parameters
Factors P‑p38 MAPK of cytoplasm






R P R P R P
Median age (years)
 Median (range) 53 (30–81) 53 (31–81) 0.037 0.357 0.001 0.988 0.017 0.848 0.176 0.036
Menopause
 Yes 103 90 0.002 0.687 −0.039 0.558 −0.018 0.87 0.19 0.058
 No 91 71
Depth of invasion
 T1 73 57 0 0.999 0.042 0.517 −0.063 0.543 −0.03 0.759
 T2/T3/T4 121 104
Regional lymph node metastasis
 Negative (N0) 60 93 0.016 0.72 0.027 0.662 0.026 0.795 −0.024 0.807
 Positive (N1/N2/N3) 134 68
Stage
 I 60 49 −0.077 0.098 −0.046 0.463 −0.158 0.127 −0.088 0.365
 II/III 134 112
Histologic grade
 I 13 10 −0.034 0.474 0.003 0.961 −0.204 0.057 −0.067 0.5
 II/III 181 151
Histologic type
 Ductal 182 148 0.009 0.85 −0.041 0.533 0.147 0.173 −0.011 0.912
 Lobular 12 13
ER
 Negative 86 77 0.013 0.775 0.148 0.025 – – – –
 Positive 108 84
PR
 Negative 122 93 0.083 0.078 0.22 0.001 – – – –
 Positive 72 68
Her2
 Negative 108 93 0.015 0.745 0.029 0.646 0.31 0.003 – –
 Positive 86 68
P-p38 MAPK of nucleus
 Negative 163 9 0.772 0.000 0.784 0.000 0.812 0.000 0.717 0.000
 Positive 31 152
Factors P‑p38 MAPK of nucleus






R P R P R P
Median age (years)
 Median (range) 53 (30–59) 53 (31–81) 0.028 0.479 0.012 0.817 0.037 0.684 0.099 0.234
Menopause
 Yes 95 98 −0.019 0.691 −0.043 0.507 0.005 0.965 0.042 0.671
 No 77 85
Depth of invasion
 T1 60 70 −0.026 0.586 0.005 0.935 −0.042 0.684 −0.059 0.542
 T2/T3/T4 112 113
Regional lymph node metastasis
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p38α, β, γ and δ) peculiarly and does not cross-react with 
the phosphorylated forms of either p42/44 MAPK or 
SAPK/JNK (Kuroyanagi et al. 2015; Kanno et al. 2005). So 
our results are based on p38 MAP kinase, including the 
four subtypes mentioned above, and not a single one of 
them.
P38 MAPK have been shown to be present in both 
the nucleus and the cytoplasm of quiescent cells before 
(Cuenda and Rousseau 2007). Consist with this, our 
study showed that P-p38 MAPK was expressed not only 
in the cytoplasm but also in nucleus of breast cancer cells 
and showed a strongly positive correlation between the 
expression in cytoplasm and in nucleus (Table 1). Upon 
cell stimulation, some evidence suggests that p38 MAPK 
translocates from the cytoplasm to the nucleus (Rainge-
aud et  al. 1995) after phosphorylation while other data 
Table 2 continued
Factors P‑p38 MAPK of nucleus






R P R P R P





 I 49 60 −0.087 0.061 −0.068 0.272 −0.108 0.295 −0.129 0.182
 II/III 123 123
Histologic grade
 I 10 13 −0.092 0.05 −0.052 0.408 −0.135 0.21 −0.143 0.148
 II/III 162 170
Histologic type
 Ductal 160 170 −0.005 0.924 −0.063 0.333 0.212 0.05 −0.073 0.462
 Lobular 12 13
ER
 Negative 82 81 0.07 0.127 0.122 0.053 – – – –
 Positive 90 102
PR
 Negative 116 99 0.171 0.000 0.225 0.000 – – – –
 Positive 56 84
Her2
 Negative −0.006 0.894 −0.018 0.771 0.257 0.013 – –
 Positive 82 72
P-p38 MAPK of nucleus
 Negative – – 0.784 0.000 0.812 0.003 0.727 0.000
 Positive – –
Table 3 Multivariate analysis by logistic regression analysis
Breast cancer Dependent variable Independent variable SE P value OR 95 % CI
Overall P-p38 MAPK of cytoplasm PR 0.234 0.008 1.866 1.178–2.954
P-p38 MAPK of nucleus PR 0.246 0 2.469 1.524–3.999
Luminal A/B P-p38 MAPK of cytoplasm PR 0.292 0.008 2.172 1.225–3.851
P-p38 MAPK of nucleus PR 0.308 0 2.952 1.615–5.97
HER2-positive P-p38 MAPK of cytoplasm HER2 0.294 0.009 2.145 1.206–3.816
P-p38 MAPK of nucleus HER2 0.287 0.03 1.868 1.063–3.281
Triple negative P-p38 MAPK of cytoplasm/nucleus None – – – –
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are consistent with activation of p38 within the nucleus 
followed by its movement to the cytoplasm. Generally, 
the different locations maybe imply their different func-
tions. As such, the exact function of P-p38 MAPK in 
cytoplasm and nucleus in breast cancer should be gone 
further study in future.
The aim of our study was to clarify the correlation 
between P-p38 MAPK expression and clinicopatho-
logical parameters through correlation analysis and to 
further explore possible factors affecting its expression 
through multivariate logistic regression analysis.
The p38 MAPK signaling pathway plays an impor-
tant role in breast cancer invasion and metastasis (Han 
et  al. 2007; del Barco and Nebreda 2012). In our study, 
we found that, none of the various clinicopathologi-
cal parameters, such as age, menopause status, depth of 
invasion, histological classification, regional lymph node 
metastasis, histological type, lymph node metastasis 
and AJCC stage status, was significantly correlated with 
P-p38 MAPK expression (Table 2).
Our study also showed that PR was the only one that 
was positively correlated with P-p38 MAPK in cyto-
plasm, but not in nucleus, among the three critical fac-
tors, ER, PR and HER2 in overall data. As the products 
of the connection between estrogen and its receptor, PRs 
only appear in ER+ breast cancer (luminal A/B subtype), 
as expected, this kind of positive correlation existed only 
in patients with luminal A/B subtype. PR was also dem-
onstrated the only one which was a significant associa-
tion in luminal A/B breast cancer in multivariate logistic 
regression analysis. As members of the steroid hormone 
receptor family, PRs are able to interact with and activate 
p38 MAP kinase function as part of signaling cascades 
(Schiff et  al. 2004; Dressing et  al. 2009) and might play 
an important role in breast cancer progression via the 
MAPK signal pathway (Treviño et al. 2013). This is simi-
lar to the fact that steroid hormone-induced rapid activa-
tion of MAPK appears to be most robust when both ER 
and PR are coexpressed (Migliaccio et  al. 1998; Ballaré 
et  al. 2003). Endocrine therapy in breast cancer aims to 
disrupt estrogen stimulation of the cancer cells, which 
are mediated via binding to the ER/PR. Luminal A/B 
type breast cancers coexpressing ER and PR are generally 
more sensitive to endocrine therapy than ER alone and 
perhaps the “more tumoral sensitivity” maybe partly due 
to lessening the level of P-p38MAPK through disrupting 
the hormone receptor PR.
P38 signaling has been verified to drive trastuzumab 
resistance and invasiveness in HER2-overexpressing 
breast cancer. At last, we found a positive correlation 
between P-p38 MAPK expression and HER2 in HER2-
positive but not in overall breast cancer, luminal A/B 
and even in HER2 positive luminal B breast cancer. 
As contrary, nothing significant correlation was found 
between P-p38 MAPK expression and PR in HER2 pos-
itive luminal B breast cancer. In one hand, these results 
might advocate that HER2 could play an important 
role in expression of P-p38 MAPK, and on the other 
hand, our results might imply that country to HER2, PR 
might be more important than HER2 in P-p38 MAPK 
in breast cancer which is worthy of going further study 
in future.
A lot of publications in the past have shown that devel-
opment of tamoxifen resistance during the short-time 
period of neoadjuvant therapy was accomplished by loss 
of PR and an increase in HER2, as well as activated p38 
MAPK (Gutierrez et  al. 2005; Linderholm et  al. 2011). 
Probably the up-regulated expression of HER2, which 
could induce the phosphorylation of p38 MAPK, could 
also restrain ER/PR expression in luminal B type (Fan 
et al. 2015; Daniel et al. 2011). These opposite expression 
of PR and P-p38 that predominately activated by HER2, 
might be used to interpret not only our finding, but also 
endocrine therapy resistance in patients with HER2 posi-
tive luminal B breast cancer. Even though, both the exact 
con-relationship between PR and P-p38 MAPK, and the 
effects of P-p38 MAPK expression on the progress of 
breast cancer in PR positive luminal A/B breast cancer 
are still both worthy of going further study in future. In 
addition, there are many of other markers that may be 
correlated with the main prognostic, such as CD44+/
CD24−/low biomarker (Camerlingo et al. 2014; de Beça 
et al. 2013), and epidermal growth factor receptor (Cas-
sol et  al. 2010), etc. The corelatioship between those 
markers and P-p38MAPK merits further study in future 
to explore which one is more effective than the other.
As for the limitation of sample size, larger numbers of 
patient samples are still required to conclusively deter-
mine the biological significance of P-p38 MAPK in 
patients with invasive breast cancer. Total p38 MAPK 
also needs to be detected together to show which one is 
more reliable factor to predict patient survival in future 
although the active form of p38 MAPK is more really 
reflect its function than the inactive one in breast cancer.
Conclusions
P-p38 MAPK was significantly associated with PR in 
luminal A/B subtype and with HER2 expression in 
HER2-positive subtype breast cancer. PR/HER2 might 
association with phosphorylation of p38 MAPK in dif-
ferent subtype breast cancer and further studies will 
be needed to conform this mechanism. Our study and 
further mechanism research will not only help us real-
ize the role p38 MAPK play and the infect of PR/HER2 
on their phosphorylation, but also could provide more 
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effective means to prevent the progress of tumor in 
breast cancer.
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